Treatment of Pulmonary Hypertension with Carbonic Anhydrase Inhibitors

Abstract

This disclosure relates generally to methods and pharmaceutical compositions useful in treating pulmonary hypertension. In one embodiment, for example, the disclosure provides a method for treating pulmonary hypertension comprising administering a therapeutically effective dose of a carbonic anhydrase inhibitor to a patient in need of treatment. The disclosure finds utility in the fields of medicine and pharmacology.

1 - 65 . (canceled) 
     
     
         66 . A method of treating chronic obstructive pulmonary disease in a subject in need thereof comprising administering a therapeutically effective amount of topiramate, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a Type V phosphodiesterase inhibitor, or a pharmaceutically acceptable salt thereof, thereby treating chronic obstructive pulmonary disease. 
     
     
         67 . The method of  claim 66 , wherein the type V phosphodiesterase inhibitor is avanafil, sildenafil, tadalafil, zaprinast, dipyridamole, or vardenafil, or pharmaceutically acceptable salts thereof. 
     
     
         68 . The method of  claim 66 , wherein the type V phosphodiesterase inhibitor is sildenafil, or pharmaceutically acceptable salt thereof. 
     
     
         69 . The method of  claim 66 , wherein the topiramate is contained in a pharmaceutical formulation that further comprises at least one pharmaceutically acceptable excipient. 
     
     
         70 . The method of  claim 69 , wherein the pharmaceutical formulation is a controlled release dosage form. 
     
     
         71 . The method of  claim 70 , wherein the controlled release dosage form provides for sustained release of the topiramate following administration of the dosage form. 
     
     
         72 . The method of  claim 71 , wherein the formulation provides for a substantially constant plasma level of the topiramate over a time period in the range of about 4 to 12 hours. 
     
     
         73 . The method of  claim 66 , wherein the topiramate is administered in an amount in the range of about 10 mg to about 400 mg per day. 
     
     
         74 . The method of  claim 66 , wherein the topiramate is administered in an amount in the range of about 50 mg to about 250 mg per day. 
     
     
         75 . The method of  claim 66 , wherein the topiramate is administered in an amount in the range of about 75 mg to about 225 mg per day. 
     
     
         76 . The method of  claim 66 , wherein the initial daily dosage is in the range of about 10 mg to about 40 mg. 
     
     
         77 . The method of  claim 66 , wherein the initial daily dosage is in the range of about 15 mg to about 35 mg. 
     
     
         78 . The method of  claim 66 , wherein the weight ratio of topiramate administered to the Type V phosphodiesterase inhibitor administered is in the range of about 6:1 to about 1:1.5. 
     
     
         79 . The method of  claim 66 , wherein the weight ratio of topiramate administered to the Type V phosphodiesterase inhibitor administered is in the range of about 4:1 to about 1:1. 
     
     
         80 . The method of  claim 66 , wherein the topiramate and the Type V phosphodiesterase inhibitor are administered at different times of the day. 
     
     
         81 . The method of  claim 66 , wherein the topiramate and the Type V phosphodiesterase inhibitor are administered simultaneously. 
     
     
         82 . The method of  claim 66 , wherein the topiramate and the Type V phosphodiesterase inhibitor are contained in a single formulation. 
     
     
         83 . The method of  claim 82 , wherein the single formulation comprises an orally administrable dosage form that provides for controlled release of the topiramate, and either immediate release or controlled release of the Type V phosphodiesterase inhibitor. 
     
     
         84 . The method of  claim 83 , wherein the single formulation provides for controlled release of the phosphodiesterase inhibitor. 
     
     
         85 . The method of  claim 83 , wherein the single formulation provides for sustained release of the phosphodiesterase inhibitor.